title: In vitro neutron irradiation of glioma and endothelial cultured cells.
abstract: To fully develop its potential boron neutron capture therapy (BNCT) requires the combination of a suitable thermal/epithermal neutron flux together with a selective intake of (10)B-boron nuclei in the target tissue. The latter condition is the most critical to be realized as none of the boron carriers used for experimental or clinical purposes proved at the moment an optimal selectivity for cancer cells compared to normal cells. In addition to complex physical factors, the assessment of the intracellular concentration of boron represent a crucial parameter to predict the dose delivered to the cancer cells during the treatment. Nowadays the dosimetry calculation and then the prediction of the treatment effectiveness are made using Monte Carlo simulations, but some of the model assumption are still uncertain: the radiobiological dose efficacy and the probability of tumour cell survival are crucial parameters that needs a more reliable experimental approach. The aim of this work was to evaluate the differential ability of two cell lines to selectively concentrate the boron-10 administered as di-hydroxyboryl-phenylalanine (BPA)-fructose adduct, and the effect of the differential boron intake on the damage produced by the irradiation with thermal neutrons; the two cell lines were selected to be representative one of normal tissues involved in the active/passive transport of boron carriers, and one of the tumour. Recent in vitro studies demonstrated how BPA is taken by proliferating cells, however the mechanism of BPA uptake and the parameters driving the kinetics of influx and the elimination of BPA are still not clarified. In these preliminary studies we analysed the survival of F98 and human umbilical vein endothelial cells (HUVEC) cells line after irradiation, using different thermal fluencies at the same level of density population and boron concentration in the growing medium prior the irradiation. This is first study performed on endothelium model obtained by a primary human cell line (HUVEC). The perspective application of this work is to develop a model able to foresee the effects produced by different combination of boron influx with a thermal neutron fluencies, applying a standardized radiobiological methodology, and in particular to continue the investigation of the radiobiological effects on the endothelium model as the main tissue involved in the transport of boronated molecules.
authors.affiliation: Department of PET and Radiopharmaceutical Chemistry, C.N.R. Institute of Clinical Physiology, Pisa, Italy. luca.menichetti@ifc.cnr.it
authors.forename: L
authors.initials: L
authors.lastname: Menichetti
authors.forename: L
authors.initials: L
authors.lastname: Gaetano
authors.forename: A
authors.initials: A
authors.lastname: Zampolli
authors.forename: S
authors.initials: S
authors.lastname: Del Turco
authors.forename: C
authors.initials: C
authors.lastname: Ferrari
authors.forename: S
authors.initials: S
authors.lastname: Bortolussi
authors.forename: S
authors.initials: S
authors.lastname: Stella
authors.forename: S
authors.initials: S
authors.lastname: Altieri
authors.forename: P A
authors.initials: PA
authors.lastname: Salvadori
authors.forename: L
authors.initials: L
authors.lastname: Cionini
mesh_terms: D000818:Animals; D001896:Boron Compounds / Q000009:adverse effects / Q000627:therapeutic use; D016754:Boron Neutron Capture Therapy / Q000009:adverse effects / Q000379:methods* / Q000706:statistics & numerical data; D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D042783:Endothelial Cells / Q000166:cytology / Q000528:radiation effects*; D005214:Fast Neutrons / Q000009:adverse effects / Q000627:therapeutic use*; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005910:Glioma / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D066298:In Vitro Techniques; D009010:Monte Carlo Method; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use; D011874:Radiometry / Q000706:statistics & numerical data; D051381:Rats
chemical_list: C089739:4-boronophenylalanine-fructose; D001896:Boron Compounds; D011838:Radiation-Sensitizing Agents; D005632:Fructose